
Takeda reportedly sets $15bn on US acquisitions
pharmafile | September 14, 2016 | News story | Manufacturing and Production, Research and Development |Â Â Takeda, acquisitionsÂ
Takeda Pharmaceuticals is reportedly willing to spend as much as $15 billion on acquisitions in the US in efforts to expand its business, the Financial Times has reported.
It has not been determined whether the sizeable pool of funds will be used in one single acquisition or several smaller purchases.
The Japanese drugmaker declined to confirm the report, however, with a spokesman from the company remarking: “This is not something that we have announced so we cannot comment. We are looking for opportunities, including acquisitions to grow our business, but M&A is not everything.”
Matt Fellows
Related Content

Ofichem acquires US drug substance CDMO Kinentia
Ofichem has agreed to acquire Kinentia Biosciences, a US drug substance contract development and manufacturing …

Von Willebrand disease – increasing awareness and access to vital care
Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …

Combination treatments: Takeda’s Implementation Framework and the broader landscape
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …






